Ignite Creation Date:
2025-12-25 @ 1:26 AM
Ignite Modification Date:
2025-12-26 @ 1:43 AM
Study NCT ID:
NCT05792293
Status:
UNKNOWN
Last Update Posted:
2023-04-06
First Post:
2023-03-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity
Sponsor:
Ain Shams University
Organization:
Study Overview
Official Title:
Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity
Status:
UNKNOWN
Status Verified Date:
2023-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims at evaluating the role of Atorvastatin in prevention of Anthracycline induced cardiotoxicity
Detailed Description:
The study participants are female patients with breast cancer receiving Anthracycline based chemotherapy.
They will be divided into 2 groups , the first group will receive 40 mg oral atorvastatin through out the study , while the other group will receive a placebo.
Full echocardiographic study including 3D echocardiography will be done to all patients before starting their chemotherapy and after 6 months.
They will be divided into 2 groups , the first group will receive 40 mg oral atorvastatin through out the study , while the other group will receive a placebo.
Full echocardiographic study including 3D echocardiography will be done to all patients before starting their chemotherapy and after 6 months.
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: